Trupanion, Inc. (NASDAQ:TRUP – Get Free Report) CFO Fawwad Qureshi sold 6,111 shares of the business’s stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $30.01, for a total value of $183,391.11. Following the transaction, the chief financial officer owned 4,230 shares in the company, valued at approximately $126,942.30. This trade represents a 59.09% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Trupanion Trading Down 0.1%
Shares of NASDAQ:TRUP opened at $29.62 on Friday. The business’s 50-day moving average is $27.00 and its 200 day moving average is $26.00. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.77 and a quick ratio of 1.77. Trupanion, Inc. has a 1 year low of $21.16 and a 1 year high of $46.98. The firm has a market capitalization of $1.30 billion, a P/E ratio of 55.89, a P/E/G ratio of 2.00 and a beta of 1.39.
Trupanion (NASDAQ:TRUP – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The financial services provider reported $0.16 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.05. Trupanion had a return on equity of 5.96% and a net margin of 1.53%.The business had revenue of $392.93 million for the quarter, compared to analyst estimates of $389.72 million. During the same quarter in the previous year, the firm earned $0.22 earnings per share. The company’s revenue was up 11.1% on a year-over-year basis. On average, research analysts predict that Trupanion, Inc. will post 0.63 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Trupanion
Analyst Upgrades and Downgrades
TRUP has been the topic of a number of recent analyst reports. Zacks Research lowered shares of Trupanion from a “strong-buy” rating to a “hold” rating in a research note on Monday, August 24th. Stifel Nicolaus boosted their price objective on shares of Trupanion from $28.00 to $29.00 and gave the company a “hold” rating in a report on Thursday, August 20th. Atlantic Securities set a $42.00 target price on Trupanion in a research report on Wednesday, July 15th. Piper Sandler lowered Trupanion from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $45.00 to $32.00 in a research note on Wednesday. Finally, Weiss Ratings raised Trupanion from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday. One equities research analyst has rated the stock with a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Trupanion has an average rating of “Hold” and a consensus price target of $39.20.
Check Out Our Latest Research Report on Trupanion
About Trupanion
Trupanion, Inc is a pet medical insurance company that provides comprehensive insurance coverage for cats and dogs. The company’s core offering is a single, customizable medical policy designed to cover veterinary diagnostic tests, surgeries, hospital stays and congenital or hereditary conditions. Trupanion seeks to streamline the claims process by offering direct payment options to participating veterinarians, reducing the need for upfront payments by pet owners.
Founded in 1999 by Darryl Rawlings and headquartered in Seattle, Washington, Trupanion began operations in the early 2000s and has grown its presence through both digital channels and partnerships with veterinary hospitals.
See Also
- Five stocks we like better than Trupanion
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for Trupanion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trupanion and related companies with MarketBeat.com's FREE daily email newsletter.
